Article | June 29, 2022

Accelerating PROTAC Programs To Drug The "Undruggable"

Lab cell and gene pipette GettyImages-162264253

PROteolysis TArgeting Chimeras (PROTACs) have garnered a lot of attention in recent times for their ability to exploit the cell’s own degradation machinery to irreversibly degrade target proteins.

In this point of view, we discuss how Syngene can help you move your PROTAC programs from hit to lead to the clinic with speed. We are a one-stop solution for all targeted protein degradation (TPD) research requirements across a variety of molecules, including heterobifunctional degraders and molecular glue degraders. Our experience allows us to create a roadmap for X-TACs research programs, supported at each stage by our experienced team of scientists across chemistry and biology.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online